عنوان مقاله [English]
Background: Ischemic heart disease (IHD) is a cardiovascular disease, in which inflammation plays a key role. The immune cells (white blood cells) and interleukins play a very important role in inflammation and the invasion and migration of leukocytes to the site of inflammation. The aim of this study was to evaluate the serum level of interleukin 17 in patients with IHD and its relationship with the risk factors for the disease.
Methods: A total of 300 patients with IHD were included in this study. The patients were divided into three equal groups, namely, acute myocardial infarction (AMI), stable angina (SA), and unstable angina (UA). Also, one group was considered as the control group. Serum levels of interleukin 17 were measured by ELISA kit, according to the manufacturer's instructions.
Results: Serum levels of IL-17 in the AMI, SA, UA, and control groups were 6.08 ± 1.12, 5.81 ± 1.05, 7.11 ± 1.37, and 3.46 ± 0.90, respectively. Statistical analysis showed that the difference between different groups of patients and the control group was significant (P<0.01). There was no significant differences in the serum level of interleukin 17 between different groups of patients (P>0.05). The sSerum levels of interleukin 17 in diabetic patients were significantly higher than those in non-diabetic patients (P<0.03).
Conclusion: The results showed that the serum levels of interleukin 17 were associated with ischemic heart disease, and mechanisms related to interleukin 17 were associated with IHD. Interleukin 17 is an inflammatory interleukin, which is associated with increased inflammation in the pathogenesis of IHD. Diabetes mellitus may increase inflammatory factors, such as interleukin 17, like pre-inflammatory interleukins, therefore, it is associated with the pathogenesis of IHD.